Abbott Q2 Sales Rise 13%, Raises Full-Year EPS Guidance on Diagnostics and Device Strength

summarizeSummary

Abbott reported Q2 2026 sales of $12.6 billion, up 13% reported, with adjusted EPS of $1.31. The company raised its full-year adjusted EPS guidance to $5.45–$5.60 and reaffirmed comparable sales growth of 6.5%–7.5%.

check_boxKey Events · Earnings and Guidance · ABT

• Q2 Sales Up 13% Reported

  Total sales reached $12.6 billion, with 4.8% comparable growth. Diagnostics surged 42.3% reported (2.9% comparable) driven by the Exact Sciences acquisition, while Medical Devices grew 9.0% reported (8.4% comparable).

• Adjusted EPS Beats, Guidance Raised

  Adjusted diluted EPS of $1.31 exceeded expectations. Full-year adjusted EPS guidance raised to $5.45–$5.60 from $5.38–$5.58, and Q3 adjusted EPS guided to $1.38–$1.46.

• Pipeline Milestones Achieved

  CE Mark secured for Libre Duo dual glucose-ketone sensor; FDA submission completed for Amulet 360 LAA device; TECTONIC IVL pivotal trial enrollment completed.

• GAAP EPS Impacted by Acquisition Charges

  GAAP diluted EPS was $0.53, reflecting $1.36 billion in after-tax specified items including intangible amortization, acquisition costs, and a $385 million legal reserve.

auto_awesomeAnalysis · ABT · Life Sciences

Abbott delivered a strong second quarter with 13% reported sales growth, driven by the Exact Sciences acquisition and solid organic performance in Medical Devices and Established Pharmaceuticals. Adjusted EPS of $1.31 beat expectations, and management raised full-year adjusted EPS guidance to $5.45–$5.60, signaling confidence in accelerating momentum through the second half. The quarter also featured notable pipeline progress, including CE Mark for the Libre Duo glucose-ketone sensor and an FDA submission for the Amulet 360 LAA device. While GAAP earnings were weighed down by acquisition-related charges and legal reserves, the underlying business is performing well, and the raised guidance is a clear positive for investors.